MiNK Therapeutics (INKT) Competitors $0.71 -0.01 (-1.39%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends INKT vs. CELU, ELEV, CYAD, ATRA, DTIL, PYRGF, SNTI, TLSA, GNLX, and FBLGShould you be buying MiNK Therapeutics stock or one of its competitors? The main competitors of MiNK Therapeutics include Celularity (CELU), Elevation Oncology (ELEV), Celyad Oncology (CYAD), Atara Biotherapeutics (ATRA), Precision BioSciences (DTIL), PyroGenesis Canada (PYRGF), Senti Biosciences (SNTI), Tiziana Life Sciences (TLSA), Genelux (GNLX), and FibroBiologics (FBLG). MiNK Therapeutics vs. Celularity Elevation Oncology Celyad Oncology Atara Biotherapeutics Precision BioSciences PyroGenesis Canada Senti Biosciences Tiziana Life Sciences Genelux FibroBiologics MiNK Therapeutics (NASDAQ:INKT) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends. Do analysts recommend INKT or CELU? MiNK Therapeutics currently has a consensus price target of $9.00, suggesting a potential upside of 1,169.39%. Given MiNK Therapeutics' higher probable upside, research analysts clearly believe MiNK Therapeutics is more favorable than Celularity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Celularity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Which has preferable earnings & valuation, INKT or CELU? MiNK Therapeutics has higher earnings, but lower revenue than Celularity. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiNK TherapeuticsN/AN/A-$22.46M-$0.49-1.45Celularity$22.77M1.39-$196.29MN/AN/A Do insiders and institutionals believe in INKT or CELU? 2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 19.7% of MiNK Therapeutics shares are owned by insiders. Comparatively, 20.7% of Celularity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is INKT or CELU more profitable? MiNK Therapeutics has a net margin of 0.00% compared to Celularity's net margin of -460.34%. Celularity's return on equity of 65.58% beat MiNK Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MiNK TherapeuticsN/A N/A -233.85% Celularity -460.34%65.58%20.96% Which has more volatility & risk, INKT or CELU? MiNK Therapeutics has a beta of 0.06, suggesting that its stock price is 94% less volatile than the S&P 500. Comparatively, Celularity has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Does the MarketBeat Community prefer INKT or CELU? MiNK Therapeutics received 5 more outperform votes than Celularity when rated by MarketBeat users. Likewise, 72.22% of users gave MiNK Therapeutics an outperform vote while only 42.11% of users gave Celularity an outperform vote. CompanyUnderperformOutperformMiNK TherapeuticsOutperform Votes1372.22% Underperform Votes527.78% CelularityOutperform Votes842.11% Underperform Votes1157.89% Does the media refer more to INKT or CELU? In the previous week, MiNK Therapeutics had 3 more articles in the media than Celularity. MarketBeat recorded 3 mentions for MiNK Therapeutics and 0 mentions for Celularity. MiNK Therapeutics' average media sentiment score of 0.00 equaled Celularity'saverage media sentiment score. Company Overall Sentiment MiNK Therapeutics Neutral Celularity Neutral SummaryMiNK Therapeutics beats Celularity on 7 of the 13 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INKT vs. The Competition Export to ExcelMetricMiNK TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.03M$3.16B$5.40B$8.53BDividend YieldN/A1.77%5.13%4.14%P/E Ratio-1.4512.18115.5615.18Price / SalesN/A332.351,484.3492.77Price / CashN/A148.6339.6634.07Price / Book-1.364.024.665.02Net Income-$22.46M-$42.25M$119.06M$225.46M7 Day Performance0.04%8.06%0.80%0.37%1 Month Performance-4.83%8.71%5.65%3.57%1 Year Performance-31.17%32.10%36.76%29.44% MiNK Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INKTMiNK Therapeutics2.0953 of 5 stars$0.71-1.4%$9.00+1,169.4%-30.5%$28.03MN/A-1.4530News CoverageGap UpCELUCelularity0.068 of 5 stars$1.71-8.1%N/A-33.1%$33.12M$33.52M0.00220Gap UpELEVElevation Oncology1.956 of 5 stars$0.60+1.7%$7.80+1,209.4%+23.2%$35.21MN/A-0.7040Upcoming EarningsCYADCelyad OncologyN/A$0.60flatN/A+0.0%$15.91M$110,000.000.0095High Trading VolumeATRAAtara Biotherapeutics3.5786 of 5 stars$8.83+2.7%$14.00+58.6%-69.2%$42.53M$62.39M-0.22165Upcoming EarningsGap UpDTILPrecision BioSciences4.035 of 5 stars$8.28-1.1%$39.50+377.1%-24.6%$57.35M$87.64M39.83200Upcoming EarningsPYRGFPyroGenesis CanadaN/A$0.58flatN/AN/A$103.75M$9.14M-8.3090SNTISenti Biosciences1.743 of 5 stars$2.24+4.2%N/A-24.6%$102.49M$255,000.00-0.184Positive NewsTLSATiziana Life Sciences1.4345 of 5 stars$0.99flatN/A+44.6%$102.09MN/A0.008News CoverageGap DownGNLXGenelux2.8516 of 5 stars$2.96+16.1%$22.33+654.5%-79.7%$101.68M$8,000.00-3.0810Analyst ForecastShort Interest ↓News CoverageGap UpFBLGFibroBiologics2.7314 of 5 stars$2.82-1.1%$12.00+325.5%N/A$100.73MN/A0.0010Upcoming EarningsAnalyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies Celularity Competitors Elevation Oncology Competitors Celyad Oncology Competitors Atara Biotherapeutics Competitors Precision BioSciences Competitors PyroGenesis Canada Competitors Senti Biosciences Competitors Tiziana Life Sciences Competitors Genelux Competitors FibroBiologics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INKT) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
